Form 4: Recursion Pharmaceuticals CEO Sells Shares
Insider Transaction (Form 4)
Najat Khan, CEO and President and a Director of Recursion Pharmaceuticals, Inc., sold 22,408 shares of common stock on September 8, 2026 for $3.52 per share.
Summary
- Open-market sale: disposed of 22,408 Class A Common Stock at $3.52 ($78,822) on September 8, 2026; holds 2,072,890 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $78,822 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Najat Khan — Director, Officer (CEO and President)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-08 | Open-market sale | Class A Common Stock | 22,408 | $4 | $78.8K | 2,072,890 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-08 | Open-market sale (22,408 shares) |
Keywords
insider transaction, Form 4, RXRX, RECURSION PHARMACEUTICALS, INC., bearish, Najat Khan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.